{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:30Z","timestamp":1792782570901,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/National Institute of Child Health and Human Development","award":["P50 HD106446-01S1"],"award-info":[{"award-number":["P50 HD106446-01S1"]}]},{"name":"National Institute of Health (NIH)\/National Institute of General Medical Sciences","award":["R01-GM124109"],"award-info":[{"award-number":["R01-GM124109"]}],"id":[{"id":"https:\/\/ror.org\/04q48ey07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>High-dose methotrexate is an effective treatment for adult and pediatric patients with acute lymphoblastic leukemia, osteosarcoma, and lymphoma. However, its clearance is highly variable, and delayed clearance can lead to significant toxicity. This study aimed to identify a population pharmacokinetic model that accurately characterizes high-dose methotrexate clearance in an adult population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a new population pharmacokinetic model using a training dataset derived from a cohort of 208 adult patients who received high-dose methotrexate at Vanderbilt University Medical Center. To assess predictive performance, we evaluated both our model and several externally developed models using an independent test dataset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final model was a three-compartment model incorporating body surface area as a covariate on all pharmacokinetic parameters, and serum creatinine and sex as covariates on clearance. Our newly developed model predicted with the most accuracy and precision at the first concentration measurement, taken at 24\u00a0h. Our model, along with five external models, was selected based on predictive performance for further assessment with maximum a posteriori Bayesian forecasting to compare predictions at the individual-level. The model by Hui et al. was more accurate at 48\u00a0h, while our model performed similarly at 72\u00a0h.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest an optimal strategy for therapeutic drug monitoring and dosing decisions: use our model for prediction at the 24\u00a0h mark when no prior drug levels are available, followed by Bayesian forecasting using our new model supplemented by the Taylor model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04080-0","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T02:19:57Z","timestamp":1779502797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing"],"prefix":"10.1007","volume":"82","author":[{"given":"Marisa H.","family":"Blackman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Yelvington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"4080_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","volume":"309","author":"J Jolivet","year":"1983","unstructured":"Jolivet J, Cowan KH, Curt GA et al (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094\u20131104. https:\/\/doi.org\/10.1056\/NEJM198311033091805","journal-title":"N Engl J Med"},{"key":"4080_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gr.129668.111","volume":"22","author":"LB Ramsey","year":"2012","unstructured":"Ramsey LB, Bruun GH, Yang W et al (2012) Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 22:1\u20138. https:\/\/doi.org\/10.1101\/gr.129668.111","journal-title":"Genome Res"},{"key":"4080_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","volume":"108","author":"ZL Taylor","year":"2020","unstructured":"Taylor ZL, Mizuno T, Punt NC et al (2020) MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. Clin Pharmacol Ther 108:635\u2013643. https:\/\/doi.org\/10.1002\/cpt.1957","journal-title":"Clin Pharmacol Ther"},{"key":"4080_CR4","doi-asserted-by":"publisher","unstructured":"(2022) ACCP Abstract Booklet. Clin Pharmacol Drug Dev 11:1\u2013112. https:\/\/doi.org\/10.1002\/cpdd.1151","DOI":"10.1002\/cpdd.1151"},{"key":"4080_CR5","doi-asserted-by":"publisher","first-page":"106416","DOI":"10.1016\/j.ejps.2023.106416","volume":"186","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang C, Chen Y et al (2023) External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur J Pharm Sci Off J Eur Fed Pharm Sci 186:106416. https:\/\/doi.org\/10.1016\/j.ejps.2023.106416","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"4080_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-023-03579-0","volume":"80","author":"Y Yang","year":"2023","unstructured":"Yang Y, Liu Z, Chen J et al (2023) Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review. Eur J Clin Pharmacol 80:1\u201327. https:\/\/doi.org\/10.1007\/s00228-023-03579-0","journal-title":"Eur J Clin Pharmacol"},{"key":"4080_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-021-04305-2","volume":"88","author":"G Pesenti","year":"2021","unstructured":"Pesenti G, Foppoli M, Manca D (2021) A minimal physiologically based pharmacokinetic model for high-dose methotrexate. Cancer Chemother Pharmacol 88:595\u2013606. https:\/\/doi.org\/10.1007\/s00280-021-04305-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"4080_CR8","doi-asserted-by":"publisher","first-page":"1578033","DOI":"10.3389\/fphar.2025.1578033","volume":"16","author":"S Wei","year":"2025","unstructured":"Wei S, Zhang S, Wang D et al (2025) Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. Front Pharmacol 16:1578033. https:\/\/doi.org\/10.3389\/fphar.2025.1578033","journal-title":"Front Pharmacol"},{"key":"4080_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694\u2013703. https:\/\/doi.org\/10.1634\/theoncologist.11-6-694","journal-title":"Oncologist"},{"key":"4080_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H et al (2016) Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 21:1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"4080_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:612\u2013619. https:\/\/doi.org\/10.1002\/pbc.23074","journal-title":"Pediatr Blood Cancer"},{"key":"4080_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00228-024-03692-8","volume":"80","author":"V Komenkul","year":"2024","unstructured":"Komenkul V, Sukarnjanaset W, Komolmit P, Wattanavijitkul T (2024) External validation of population pharmacokinetic models of tacrolimus in Thai adult liver transplant recipients. Eur J Clin Pharmacol 80:1229\u20131240. https:\/\/doi.org\/10.1007\/s00228-024-03692-8","journal-title":"Eur J Clin Pharmacol"},{"key":"4080_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1787","author":"L Choi","year":"2020","unstructured":"Choi L, Beck C, McNeer E et al (2020) Development of a System for Postmarketing Population Pharmacokinetic and Pharmacodynamic Studies Using Real-World Data From Electronic Health Records Clin Pharmacol Ther 107:934\u2013943. https:\/\/doi.org\/10.1002\/cpt.1787"},{"key":"4080_CR14","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1111\/bcp.15194","volume":"88","author":"NT James","year":"2022","unstructured":"James NT, Breeyear JH, Caprioli R et al (2022) Population pharmacokinetic analysis of dexmedetomidine in children using real-world data from electronic health records and remnant specimens. Br J Clin Pharmacol 88:2885\u20132898. https:\/\/doi.org\/10.1111\/bcp.15194","journal-title":"Br J Clin Pharmacol"},{"key":"4080_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM et al (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23:52\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0243","journal-title":"Oncologist"},{"key":"4080_CR16","unstructured":"MonolixSuite Documentation https:\/\/monolixsuite.slp-software.com\/?l=en. Accessed 11 July 2025"},{"key":"4080_CR17","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/. Accessed 11 July 2025"},{"key":"4080_CR18","unstructured":"NONMEM | Nonlinear Mixed Effects Modelling | ICON plc. https:\/\/www.iconplc.com\/solutions\/technologies\/nonmem. Accessed 11 July 2025"},{"key":"4080_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000542461","volume":"70","author":"C Seydoux","year":"2025","unstructured":"Seydoux C, Briki M, Wagner AD et al (2025) Importance of Sex-Dependent Differences for Dosing Selection and Optimization of Chemotherapeutic Drugs. Chemotherapy 70:92\u2013101. https:\/\/doi.org\/10.1159\/000542461","journal-title":"Chemotherapy"},{"key":"4080_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bcp.13431","volume":"84","author":"J-J Mao","year":"2018","unstructured":"Mao J-J, Jiao Z, Yun H-Y et al (2018) External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol 84:153\u2013171. https:\/\/doi.org\/10.1111\/bcp.13431","journal-title":"Br J Clin Pharmacol"},{"key":"4080_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/phar.2379","volume":"40","author":"MP Pai","year":"2020","unstructured":"Pai MP, Debacker KC, Derstine B et al (2020) Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. Pharmacother J Hum Pharmacol Drug Ther 40:308\u2013319. https:\/\/doi.org\/10.1002\/phar.2379","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"4080_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-024-01452-6","volume":"64","author":"A Yin","year":"2025","unstructured":"Yin A, de Groot FA, Guchelaar H-J et al (2025) Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma. Clin Pharmacokinet 64:79\u201391. https:\/\/doi.org\/10.1007\/s40262-024-01452-6","journal-title":"Clin Pharmacokinet"},{"key":"4080_CR23","doi-asserted-by":"publisher","first-page":"1548203","DOI":"10.3389\/fphar.2025.1548203","volume":"16","author":"J Zhao","year":"2025","unstructured":"Zhao J, Wu R, Zhang S et al (2025) Population pharmacokinetic model of high-dose methotrexate in Chinese patients with intracranial germ cell tumors. Front Pharmacol 16:1548203. https:\/\/doi.org\/10.3389\/fphar.2025.1548203","journal-title":"Front Pharmacol"},{"key":"4080_CR24","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M et al (2019) Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol 84:1339\u20131348. https:\/\/doi.org\/10.1007\/s00280-019-03966-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4080_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","volume":"42","author":"A Nader","year":"2017","unstructured":"Nader A, Zahran N, Alshammaa A et al (2017) Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters. Eur J Drug Metab Pharmacokinet 42:221\u2013228. https:\/\/doi.org\/10.1007\/s13318-016-0338-1","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4080_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00228-024-03642-4","volume":"80","author":"B \u0160kori\u0107","year":"2024","unstructured":"\u0160kori\u0107 B, Jovanovi\u0107 M, Kuzmanovi\u0107 M et al (2024) Understanding hemoglobin contribution to high-dose methotrexate disposition-population pharmacokinetics in pediatric patients with hematological malignancies. Eur J Clin Pharmacol 80:697\u2013705. https:\/\/doi.org\/10.1007\/s00228-024-03642-4","journal-title":"Eur J Clin Pharmacol"},{"key":"4080_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bcp.14160","volume":"86","author":"JC Panetta","year":"2020","unstructured":"Panetta JC, Roberts JK, Huang J et al (2020) Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol 86:362\u2013371. https:\/\/doi.org\/10.1111\/bcp.14160","journal-title":"Br J Clin Pharmacol"},{"key":"4080_CR28","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H et al (2016) Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 21:1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"4080_CR29","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/cts.13600","volume":"16","author":"ZL Taylor","year":"2023","unstructured":"Taylor ZL, Miller TP, Poweleit EA et al (2023) Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci 16:2130\u20132143. https:\/\/doi.org\/10.1111\/cts.13600","journal-title":"Clin Transl Sci"},{"key":"4080_CR30","doi-asserted-by":"publisher","unstructured":"Zhan M et al (2022) Sun,Yiqi, Zhou, Fang, Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma. Xenobiotica 52:265\u2013273. https:\/\/doi.org\/10.1080\/00498254.2022.2069060","DOI":"10.1080\/00498254.2022.2069060"},{"key":"4080_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00280-024-04708-x","volume":"94","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Qi X, Huang X et al (2024) An interactive dose optimizer based on population pharmacokinetic study to guide dosing of methotrexate in Chinese patients with osteosarcoma. Cancer Chemother Pharmacol 94:733\u2013745. https:\/\/doi.org\/10.1007\/s00280-024-04708-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"4080_CR32","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/bjh.19365","volume":"204","author":"X Chen","year":"2024","unstructured":"Chen X, Li J, Yu L et al (2024) High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study. Br J Haematol 204:1354\u20131366. https:\/\/doi.org\/10.1111\/bjh.19365","journal-title":"Br J Haematol"},{"key":"4080_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08443-x","volume":"21","author":"U Arshad","year":"2021","unstructured":"Arshad U, Taubert M, Seeger-Nukpezah T et al (2021) Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer 21:1\u201310. https:\/\/doi.org\/10.1186\/s12885-021-08443-x","journal-title":"BMC Cancer"},{"key":"4080_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40262-018-00734-0","volume":"58","author":"RJ Beechinor","year":"2019","unstructured":"Beechinor RJ, Thompson PA, Hwang MF et al (2019) The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children\u2019s Oncology Group. Clin Pharmacokinet 58:899. https:\/\/doi.org\/10.1007\/s40262-018-00734-0","journal-title":"Clin Pharmacokinet"},{"key":"4080_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/FTD.0000000000000813","volume":"43","author":"F Gallais","year":"2021","unstructured":"Gallais F, Oberic L, Faguer S et al (2021) Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients. Ther Drug Monit 43:408. https:\/\/doi.org\/10.1097\/FTD.0000000000000813","journal-title":"Ther Drug Monit"},{"key":"4080_CR36","doi-asserted-by":"publisher","unstructured":"Gao X, Qian X-W, Zhu X-H et al (2021) Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.701452","DOI":"10.3389\/fphar.2021.701452"},{"key":"4080_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jcph.1349","volume":"59","author":"KH Hui","year":"2019","unstructured":"Hui KH, Chu HM, Fong PS et al (2019) Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. J Clin Pharmacol 59:566\u2013577. https:\/\/doi.org\/10.1002\/jcph.1349","journal-title":"J Clin Pharmacol"},{"key":"4080_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000543181","volume":"70","author":"N Maximova","year":"2025","unstructured":"Maximova N, Calabr\u00f2 PF, Cangialosi A et al (2025) Therapeutic Drug Monitoring, Population Pharmacokinetics Models, and External Validation of High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia. Chemotherapy 70:109\u2013118. https:\/\/doi.org\/10.1159\/000543181","journal-title":"Chemotherapy"},{"key":"4080_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00280-019-03977-1","volume":"85","author":"SE Medellin-Garibay","year":"2020","unstructured":"Medellin-Garibay SE, Hern\u00e1ndez-Villa N, Correa-Gonz\u00e1lez LC et al (2020) Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 85:21\u201331. https:\/\/doi.org\/10.1007\/s00280-019-03977-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4080_CR40","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","volume":"107","author":"S Mei","year":"2018","unstructured":"Mei S, Li X, Jiang X et al (2018) Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. J Pharm Sci 107:1454\u20131460. https:\/\/doi.org\/10.1016\/j.xphs.2018.01.004","journal-title":"J Pharm Sci"},{"key":"4080_CR41","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics16091180","volume":"16","author":"LB Olivo","year":"2024","unstructured":"Olivo LB, de Oliveira Henz P, Wermann S et al (2024) Anticipating Leucovorin Rescue Therapy in Patients with Osteosarcoma through Methotrexate Population Pharmacokinetic Model. Pharmaceutics 16:1180. https:\/\/doi.org\/10.3390\/pharmaceutics16091180","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04080-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04080-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:44:55Z","timestamp":1790556295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04080-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4080"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04080-0","relation":{"references":[{"id-type":"doi","id":"10.1002\/cpt.1787","asserted-by":"subject"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the VUMC Institutional Review Board (IRB #2400522). The study was determined to be exempt from the informed consent requirement due to the use of de-identified data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interests for this work.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"156"}}